TY - JOUR
T1 - Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19
AU - The COVID19hostgenomesv Consortium
AU - Sahajpal, Nikhil Shri
AU - Jill Lai, Chi Yu
AU - Hastie, Alex
AU - Mondal, Ashis K.
AU - Dehkordi, Siavash Raeisi
AU - van der Made, Caspar I.
AU - Fedrigo, Olivier
AU - Al-Ajli, Farooq
AU - Jalnapurkar, Sawan
AU - Byrska-Bishop, Marta
AU - Kanagal-Shamanna, Rashmi
AU - Levy, Brynn
AU - Schieck, Maximilian
AU - Illig, Thomas
AU - Bacanu, Silviu Alin
AU - Chou, Janet S.
AU - Randolph, Adrienne G.
AU - Rojiani, Amyn M.
AU - Zody, Michael C.
AU - Brownstein, Catherine A.
AU - Beggs, Alan H.
AU - Bafna, Vineet
AU - Jarvis, Erich D.
AU - Hoischen, Alexander
AU - Chaubey, Alka
AU - Kolhe, Ravindra
N1 - Funding Information:
J.L., A.H., and A.C. are salaried employees of Bionano Genomics Inc. R.K. has received honoraria, travel funding, and research support from Illumina, Asuragen, QIAGEN, Perkin Elmer Inc, Bionano Genomics, and BMS. A.H.B. has received funding from the NIH, MDA (USA), AFM Telethon, Alexion Pharmaceuticals Inc., Audentes Therapeutics Inc., Dynacure SAS, and Pfizer Inc. He has consulted and received compensation or honoraria from Asklepios BioPharmaceutical Inc, Audentes Therapeutics, Biogen, F. Hoffman-La Roche AG, GLG Inc, Guidepoint Global, and Kate Therapeutics, and holds equity in Ballard Biologics and Kate Therapeutics.
Funding Information:
The authors thank Christoph Lange for providing valuable feedback for the manuscript and Ben Clifford for providing technical support. Conceptualization, N.S.S. A.C. and R.K.; Data curation, N.S.S. S.J. and A.K.M.; Formal analysis, N.S.S. C.J.L. A.H. S.R.D. M.B.B. M.C.Z. F.A.A. V.B. A.C. and R.K.; Funding acquisition, R.K.; Investigation: N.S.S. C.J.L. A.H. A.C. and R.K.; Methodology: N.S.S. A.H. C.I.V.D.M. M.C.Z. C.A.B. A.H.B. V.B. E.D.J. A.H. A.C. and R.K.;. Visualization: N.S.S. C.J.L. A.H. A.C. and R.K.;. Writing?original draft: N.S.S.; Writing?review & editing: N.S.S. C.J.L. A.H. S.R.D. C.I.V.D.M. O.F. R.K.S. B.L. M.S. T.I. S.A.B. J.S.C. A.G.R. A.M.R. M.C.Z. C.A.B. A.H.B. V.B. E.D.J. A.H. A.C. and R.K. All authors have read and agreed to the published version of the manuscript. J.L. A.H. and A.C. are salaried employees of Bionano Genomics Inc. R.K. has received honoraria, travel funding, and research support from Illumina, Asuragen, QIAGEN, Perkin Elmer Inc, Bionano Genomics, and BMS. A.H.B. has received funding from the NIH, MDA (USA), AFM Telethon, Alexion Pharmaceuticals Inc. Audentes Therapeutics Inc. Dynacure SAS, and Pfizer Inc. He has consulted and received compensation or honoraria from Asklepios BioPharmaceutical Inc, Audentes Therapeutics, Biogen, F. Hoffman-La Roche AG, GLG Inc, Guidepoint Global, and Kate Therapeutics, and holds equity in Ballard Biologics and Kate Therapeutics.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/2/18
Y1 - 2022/2/18
N2 - Impressive global efforts have identified both rare and common gene variants associated with severe COVID-19 using sequencing technologies. However, these studies lack the sensitivity to accurately detect several classes of variants, especially large structural variants (SVs), which account for a substantial proportion of genetic diversity including clinically relevant variation. We performed optical genome mapping on 52 severely ill COVID-19 patients to identify rare/unique SVs as decisive predisposition factors associated with COVID-19. We identified 7 SVs involving genes implicated in two key host-viral interaction pathways: innate immunity and inflammatory response, and viral replication and spread in nine patients, of which SVs in STK26 and DPP4 genes are the most intriguing candidates. This study is the first to systematically assess the potential role of SVs in the pathogenesis of COVID-19 severity and highlights the need to evaluate SVs along with sequencing variants to comprehensively associate genomic information with interindividual variability in COVID-19 phenotypes.
AB - Impressive global efforts have identified both rare and common gene variants associated with severe COVID-19 using sequencing technologies. However, these studies lack the sensitivity to accurately detect several classes of variants, especially large structural variants (SVs), which account for a substantial proportion of genetic diversity including clinically relevant variation. We performed optical genome mapping on 52 severely ill COVID-19 patients to identify rare/unique SVs as decisive predisposition factors associated with COVID-19. We identified 7 SVs involving genes implicated in two key host-viral interaction pathways: innate immunity and inflammatory response, and viral replication and spread in nine patients, of which SVs in STK26 and DPP4 genes are the most intriguing candidates. This study is the first to systematically assess the potential role of SVs in the pathogenesis of COVID-19 severity and highlights the need to evaluate SVs along with sequencing variants to comprehensively associate genomic information with interindividual variability in COVID-19 phenotypes.
UR - http://www.scopus.com/inward/record.url?scp=85123793329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123793329&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2022.103760
DO - 10.1016/j.isci.2022.103760
M3 - Article
C2 - 35036860
AN - SCOPUS:85123793329
SN - 2589-0042
VL - 25
JO - iScience
JF - iScience
IS - 2
M1 - 103760
ER -